Theodoros Evrenoglou, Adriani Nikolakopoulou, Guido Schwarzer, Gerta Rücker, Anna Chaimani
{"title":"Producing treatment hierarchies in network meta-analysis using probabilistic models and treatment-choice criteria","authors":"Theodoros Evrenoglou, Adriani Nikolakopoulou, Guido Schwarzer, Gerta Rücker, Anna Chaimani","doi":"arxiv-2406.10612","DOIUrl":null,"url":null,"abstract":"A key output of network meta-analysis (NMA) is the relative ranking of the\ntreatments; nevertheless, it has attracted a lot of criticism. This is mainly\ndue to the fact that ranking is an influential output and prone to\nover-interpretations even when relative effects imply small differences between\ntreatments. To date, common ranking methods rely on metrics that lack a\nstraightforward interpretation, while it is still unclear how to measure their\nuncertainty. We introduce a novel framework for estimating treatment\nhierarchies in NMA. At first, we formulate a mathematical expression that\ndefines a treatment choice criterion (TCC) based on clinically important\nvalues. This TCC is applied to the study treatment effects to generate paired\ndata indicating treatment preferences or ties. Then, we synthesize the paired\ndata across studies using an extension of the so-called \"Bradley-Terry\" model.\nWe assign to each treatment a latent variable interpreted as the treatment\n\"ability\" and we estimate the ability parameters within a regression model.\nHigher ability estimates correspond to higher positions in the final ranking.\nWe further extend our model to adjust for covariates that may affect treatment\nselection. We illustrate the proposed approach and compare it with alternatives\nin two datasets: a network comparing 18 antidepressants for major depression\nand a network comparing 6 antihypertensives for the incidence of diabetes. Our\napproach provides a robust and interpretable treatment hierarchy which accounts\nfor clinically important values and is presented alongside with uncertainty\nmeasures. Overall, the proposed framework offers a novel approach for ranking\nin NMA based on concrete criteria and preserves from over-interpretation of\nunimportant differences between treatments.","PeriodicalId":501323,"journal":{"name":"arXiv - STAT - Other Statistics","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"arXiv - STAT - Other Statistics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/arxiv-2406.10612","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
A key output of network meta-analysis (NMA) is the relative ranking of the
treatments; nevertheless, it has attracted a lot of criticism. This is mainly
due to the fact that ranking is an influential output and prone to
over-interpretations even when relative effects imply small differences between
treatments. To date, common ranking methods rely on metrics that lack a
straightforward interpretation, while it is still unclear how to measure their
uncertainty. We introduce a novel framework for estimating treatment
hierarchies in NMA. At first, we formulate a mathematical expression that
defines a treatment choice criterion (TCC) based on clinically important
values. This TCC is applied to the study treatment effects to generate paired
data indicating treatment preferences or ties. Then, we synthesize the paired
data across studies using an extension of the so-called "Bradley-Terry" model.
We assign to each treatment a latent variable interpreted as the treatment
"ability" and we estimate the ability parameters within a regression model.
Higher ability estimates correspond to higher positions in the final ranking.
We further extend our model to adjust for covariates that may affect treatment
selection. We illustrate the proposed approach and compare it with alternatives
in two datasets: a network comparing 18 antidepressants for major depression
and a network comparing 6 antihypertensives for the incidence of diabetes. Our
approach provides a robust and interpretable treatment hierarchy which accounts
for clinically important values and is presented alongside with uncertainty
measures. Overall, the proposed framework offers a novel approach for ranking
in NMA based on concrete criteria and preserves from over-interpretation of
unimportant differences between treatments.